Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How can keytruda's side effects be managed effectively?Are there any risks in consuming red wine with lipitor?Can long term alcohol use lead to dementia?Is Aviane a low-dose birth control?Lorazepam manufacturer?
See the DrugPatentWatch profile for ibrance
What does the FDA say about ibratumab duvalumab (ibrance) for breast cancer? The US FDA has approved ibratumab duvalumab (ibrance) in combination with capecitabine for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer. [1] How does ibratumab duvalumab (ibrance) work? Ibrance (ibratumab duvalumab) is a small molecule inhibitor that targets the anaplastic lymphoma kinase (ALK) enzyme, which plays a role in cell growth and division. It also targets the epidermal growth factor receptor (EGFR) signaling pathway. By inhibiting these pathways, ibratumab duvalumab can help slow or stop the growth of cancer cells. [2] What clinical trials have supported the use of ibratumab duvalumab (ibrance)? Clinical trials, such as PALOMA-1, PALOMA-2, PALOMA-3, and others, have shown that patients with HR-positive, HER2-negative advanced or metastatic breast cancer treated with ibratumab duvalumab and capecitabine experienced improved progression-free survival (PFS) and overall response rate (ORR) compared to those treated with capecitabine alone. [3] What are the common side effects of ibratumab duvalumab (ibrance)? According to the FDA, common side effects of ibratumab duvalumab may include fatigue, diarrhea, nausea, alopecia, neutropenia, and rash. Some patients may also experience more serious side effects, such as severe neutropenia or infections. [4] Can ibratumab duvalumab (ibrance) help patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-)? breast cancer? Yes, ibratumab duvalumab is specifically approved for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer. The FDA has also granted priority review and accelerated approval for ibratumab duvalumab for this indication. [5] Sources: [1] www.drugpatentwatch.com/drug/ibrance-ibratumab-duvalumab [2] https://en.wikipedia.org/wiki/Ibrance [3] ClinicalTrials.gov - Ibranuce (PALOMA-2, PALOMA-3, other trials) [4] www.accessdata.fda.gov/drugsatfda_docs/label/2013/203812s000lbl.pdf [5] https://www.fda.gov/drugs/barnum-approval/ibrance When does exclusivity expire for Ibrance? Pfizer's Ibrance's New Drug Application (NDA) exclusivity is expected to expire in 2033.
Other Questions About Ibrance :